Baird Financial Group’s Indivior Pharmaceuticals INDV Stock Holding History

Baird Financial Group’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Buy	+5,142	New	+$187K	﹤0.01%	1858

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baird Financial Group's INDV Position: Q2 2026 in Review

Baird Financial Group opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 5,142 shares worth $211K. The stake represents ﹤0.01% of the portfolio and ranks #1858 among its holdings.

336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Baird Financial Group held 5,142 shares of Indivior Pharmaceuticals worth $211K as of Q2 2026.
Indivior Pharmaceuticals was a new Baird Financial Group position in Q2 2026.
Indivior Pharmaceuticals made up ﹤0.01% of Baird Financial Group's portfolio in Q2 2026, its #1858 holding.
336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Baird Financial Group's 13F filing for Q2 2026, filed 12 Aug 2026.